Etude de la densite erythrocytaire par la methode des grandients de phtalate chez les patients drepanocytaires au Chu-campus de Lome(Togo)

Kueviakoe, IM; Ayimba, E; Feteke, L; Padaro, J; Segbena, AY

doi:10.4314/jrsul.v7i2.47622

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several publications, we have found that the prevalence of martial deficiency in sickle cell disease varies between 2.5% and 11% [7,12,13]. The mean of the two prevalences is p = 6.75%.…”

Section: Methodsmentioning

confidence: 91%

“…Thus, some authors have shown that it is not necessary to prescribe iron to sickle cell patients, as iron from hemolysis is recovered for hemoglobin synthesis [4][5][6]. Based on the principle of iron recovery by the body, only folic acid supplementation for sickle cell patients is recommended [7][8][9]. At the sickle cell referral center of Lomé, iron is prescribed only to pregnant sickle cell patients to compensate the increased needs associated with pregnancy [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ferritin level in sickle cell patients at the sickle cell referral center of Lomé in 2022

Hèzouwè,

Koffi,

Mawulé Corcellar

et al. 2024

Int J Blood Transfus Immunohematol

View full text Add to dashboard Cite

Aim: Major sickle cell sufferers residing in tropical regions find themselves at the crossroads of several situations that can modify their iron status. Our aim was to describe ferritin levels in sickle cell patients at Centre National de Recherches et de Soins aux Drépanocytaires (CNRSD) of Lomé. Methods: This was a cross-sectional study of sickle cell patients seen in medical consultations from May 16 to July 15, 2022. We included all sickle cell patients with anemia, who were seen in a medical monitoring during the study period and who gave their free consent. MINDRAY automatic system BC 6000, Mini-Vidas automatic system from BIOMERIEUX, and Minicap Flex Piercing from SEBIA were used to perform hemograms, ferritin levels, protidograms, and hemoglobin electrophoresis, respectively. The variables studied were patients’ medical history, age, sex, hematimetric indices, ferritin levels, hemoglobin fractions, and protidograms. We used Statistical Package for the Social Sciences (SPSS) software to analyze data. Results: 117 patients with a mean age of 15.42±11.11 years were included. The sex ratio M/F was 0.98. Ferritin levels was below 15 ng/mL in 4 (3.42% of cases) and below 30 ng/mL in an inflammatory context in 7 patients (5.98%). Median ferritin level was 178.37 ng/mL; [Q1=59.39; Q3=411.35]. SS patients were most frequent (75.21%). The mean hemoglobin level of patients was 8.10±1.21 g/dL. Non-microcytic anemia was most frequent (57.30%). Conclusion: Elevated ferritin levels were more frequent than iron deficiency in sickle cell patients at the CNRSD of Lomé. Thus, any prescription of iron should be motivated by proof of the existence of iron deficiency.

show abstract

Section: Methodsmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Ferritin level in sickle cell patients at the sickle cell referral center of Lomé in 2022

Hèzouwè,

Koffi,

Mawulé Corcellar

et al. 2024

Int J Blood Transfus Immunohematol

View full text Add to dashboard Cite

show abstract

“…This figure is constantly rising. Since the advent of imatinib in 2005, courtesy of The Max Foundation's GIPAP (Glivec International Patient Assistance Program), patient outcomes have improved considerably [5]. The range of TKIs offered by the GIPAP program was subsequently extended with the introduction of dasatinib in 2019 and bosu-tinib in 2023.…”

Section: Introductionmentioning

confidence: 99%

Cytogenetic and Molecular Remission in Chronic Myeloid Leukemia in Togo

KMC,

et al. 2023

annhematoloncol

View full text Add to dashboard Cite

The availability of tyrosine kinase inhibitors (TKIs) in Togo through the GIPAP program has revolutionized the management of chronic myeloid leukemia and increased patient life expectancy. However, diagnosis and molecular monitoring of therapeutic efficacy remain a real challenge due to the inaccessibility of cytogenetic and molecular biology tools. We’ve conducted, a cross-sectional, descriptive study that ran from December 21, 2022, to January 20, 2023, with the aim to evaluate the cytogenetic and molecular remission in CML patients followed at the CHU Campus de Lomé in Togo. Patients diagnosed with chronic-phase CML who had been treated for at least three months with imatinib or dasatinib and had achieved complete hematological remission were included. Dosage of BCR-ABL transcript levels was performed by RQ-PCR in Seattle, USA, using Dried Blood Spot. The transcript detection limit was 0.003% i.e., MR4. A total of 38 patients were included, 68.4% of them were treated with imatinib and 31.6% with dasatinib. In terms of remission, 28.9% had not achieve a partial cytogenetic remission while 15.8% of patients had achieved a MR4 remission and 7.9% a major molecular remission. Major molecular remission was achieved at a mean follow-up time of 95 months for patients taking imatinib and 22 months for those taking dasatinib. Patients in MR4 were on imatinib after a mean of 68 months. All in one, our study showed a high rate of treatment failure. Better access to cytogenetic and molecular biology tools is needed to improve management.

show abstract

Etude de la densite erythrocytaire par la methode des grandients de phtalate chez les patients drepanocytaires au Chu-campus de Lome(Togo)

Cited by 2 publications

References 0 publications

Ferritin level in sickle cell patients at the sickle cell referral center of Lomé in 2022

Ferritin level in sickle cell patients at the sickle cell referral center of Lomé in 2022

Cytogenetic and Molecular Remission in Chronic Myeloid Leukemia in Togo

Contact Info

Product

Resources

About